Biosimilar competition is fueled in the domestic pharmaceutical market
Competition among biosimilars will get severe in the domestic pharmaceutical market.
The market, which has been steady since the launch of Celltrion’s Remsima on November 2012, is getting fueled by patent expirations of large products. Brensis, an Enbrel biosimilar, will be launched next month, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
